Last updated 2 months ago

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

380 patients around the world

Available in United States, Mexico, Argentina

Eli Lilly and Company

13Research sites

380Patients around the world

This study is for people with

Arthritis

Rheumatoid arthritis

From 18 Years

All Gender

: Have a diagnosis of adult-onset RA for at least 3 months prior to screening as defined by the 2010 ACR/European League Against Rheumatism (EULAR) classification criteria.
Have moderately-to-severely active RA at screening and baseline, defined by the presence of
≥6 swollen joints based on 66 joint count, and
≥6 tender joints based on 68 joint count.
Have had a history of failure (an inadequate response, intolerance, or loss of response) to at least 1 conventional synthetic disease modifying anti rheumatic drug (csDMARD) and either 1 biologic (bDMARD), or targeted synthetic (tsDMARD) treatment.

: Have Class IV RA according to ACR revised criteria
Have presence of 1 or more significant concurrent medical conditions per investigator judgment, including but not limited to
poorly controlled diabetes or hypertension
chronic kidney disease stage IIIa or IIIb, IV, or V
symptomatic heart failure according to New York Heart Association class II, III, or IV
myocardial infarction,unstable angina pectoris, stroke, or transient ischemic attack within the past 12 months before randomization
severe chronic pulmonary disease, for example, requiring oxygen therapy
major chronic inflammatory disease or connective tissue disease other than RA, including but not limited to
systemic lupus erythematosus
psoriatic arthritis
axial spondyloarthritis,including ankylosing spondylitis and non-radiographic axial spondyloarthritis
reactive arthritis
gout
scleroderma
polymyositis
dermatomyositis
active fibromyalgia, or
multiple sclerosis

Instituto Médico de Alta Complejidad San Isidro IMACSI

Av. del Libertador 16958, San Isidro, Buenos Aires

Instituto de Investigaciones Clínicas Zárate

Florestano Andrade 332, Zárate, Buenos Aires

Mautalen - Salud e Investigación - CABA

Azcuénaga 1860, CABA, Buenos Aires

Centro Medico de Nutrición y Diabetes (CENUDIAB)

Av. J. B. Alberdi 5763, CABA, Buenos Aires

MR Medicina Reumatológica

Recruiting

San Fernando Buenos Aires AR, Adolfo Alsina 1432 PLANTA BAJA, B1646 GHP

Köhler & Milstein Research

Av. Colón 197, García Ginerés, 97070 Mérida, Yucatán.

Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González

Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey, Nuevo León

CIMAB S.A. de C.V. - Coahuila

Calle Francisco I. Madero 270 sur Int. 2, Colonia Centro, Torreón, Coahuila

Investigación y Biomedicina de Chihuahua

Calle 16, 1600, Zona Centro, 31000 Chihuahua, Chih., México

Centro de Estudios Clínicos de Querétaro S.C.

Privada Ignacio Zaragoza poniente No.16 - Querétaro - Querétaro 76000

SponsorEli Lilly and Company

Conditions

Rheumatoid arthritis

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT05848258